reason_treatment_not_given,papillary_renal_cell_type,roots,percent_neutrophil_infiltration,ishak_fibrosis_score,project,epithelioid_cell_percent,slide_images,histone_family,residual_tumor_measurement,vital_status,to_trim_adapter_sequence,cytoband,percent_granulocyte_infiltration,days_to_treatment_end,biospecimen_supplements,methylation_liftover_workflows,igcccg_stage,second_exon
Adverse Event/Complications,Type 1,Primary,2.5,0 - No Fibrosis,Oncogene Target Discovery,5.2,H&E_stained_lung_carcinoma,H1,1-10 mm,Alive,True,1q21.1,2.5,28,Fetal Bovine Serum,Bisulfite-Seq Liftover,Good Prognosis,E2
Not Done per Treating Physician's Discretion,Type 2,Secondary,5.0,"1,2 - Portal Fibrosis",Precision Immunotherapy Trials,12.7,Immunofluorescence_labeled_breast_cancer,H2A,11-20 mm,Dead,False,3p14.2,7.8,45,Collagenase,WGBS to hg38,Intermediate Prognosis,E5
Not Reported,Type 1,Tertiary,7.8,"3,4 - Fibrous Septa",Metastasis Prevention Strategy,18.9,Papanicolaou_stain_cervical_cancer,H2B,>20 mm,Not Reported,False,5q35.3,12.3,60,Trypsin-EDTA,Cross-Species Methylation Mapping,Not Reported,E8
Participant Refusal,Type 1,Quaternary,10.3,5 - Nodular Formation and Incomplete Cirrhosis,Breast Cancer Genomics,23.5,Masson's_trichrome_stain_liver_cancer,H3,No macroscopic disease,Unknown,True,7p22.1,15.0,90,Penicillin-Streptomycin,Methylation Array to NGS Liftover,Poor Prognosis,E11
Scheduling Problems,Type 1,Metastatic,12.1,6 - Established Cirrhosis,Lung Cancer Vulnerabilities,29.0,Giemsa_stain_leukemia_blasts,H4,11-20 mm,alive,False,9q34.2,20.5,120,L-Glutamine,ENCODE Methylation Liftover,Unknown,E14
Unknown,Type 1,Basal,15.4,Not Reported,Melanoma Molecular Mapping,34.4,Periodic_acid-Schiff_colorectal_cancer,Not Reported,1-10 mm,dead,True,11p15.5,25.7,150,HEPES Buffer,Illumina Infinium Liftover,Poor Prognosis,E17
Not Done per Treating Physician's Discretion,Type 1,Squamous,18.6,Unknown,Pancreatic Cancer Early Detection,41.8,Oil_Red_O_stain_liposarcoma,Unknown,No macroscopic disease,lost to follow-up,False,13q14.2,30.1,180,Sodium Pyruvate,RRBS to GRCh38,Poor Prognosis,E20
Scheduling Problems,Type 1,Adenomatous,20.0,6 - Established Cirrhosis,Prostate Cancer Risk Factors,45.3,Wright_stain_myeloma_cells,H2B,No macroscopic disease,dead,False,15q11.2,35.4,210,Non-Essential Amino Acids,CGmap to Bismark Liftover,Good Prognosis,E23
Scheduling Problems,Type 1,Fibrous,23.5,0 - No Fibrosis,Leukemia Cell Resistance,50.0,Silver_stain_neuroendocrine_tumor,H2A,11-20 mm,lost to follow-up,True,17p13.1,40.0,240,Insulin-Transferrin-Selenium,Methylation450K Array Update,Good Prognosis,E26
Scheduling Problems,Type 1,Sarcomatous,26.8,0 - No Fibrosis,Glioblastoma Therapeutic Approaches,55.6,Alcian_blue_stain_pancreatic_cancer,H2A,No macroscopic disease,lost to follow-up,False,19q13.4,45.2,270,B-27 Supplement,Nanopore Methylation to hg19,Poor Prognosis,E29
Scheduling Problems,Type 2,Lymphoid,30.2,"3,4 - Fibrous Septa",Colorectal Cancer Screening Innovations,62.1,Congo_red_stain_amyloidosis_associated_with_myeloma,H2A,11-20 mm,lost to follow-up,True,2p21,50.6,300,N-2 Supplement,MethylKit Conversion Workflow,Poor Prognosis,E32
Scheduling Problems,Type 1,Myeloid,33.7,6 - Established Cirrhosis,Ovarian Cancer Biomarker Identification,68.3,Toluidine_blue_stain_mast_cell_tumor,H3,1-10 mm,dead,False,4q25,55.8,330,Human Serum Albumin,BSMAP to MethPipe Liftover,Poor Prognosis,E35
Scheduling Problems,Type 1,Carcinomatous,37.9,6 - Established Cirrhosis,Bladder Cancer Treatment Optimization,74.9,Mucicarmine_stain_adenocarcinoma,Unknown,11-20 mm,lost to follow-up,False,6p22.3,60.3,365,DMSO,EpicArray to WGBS Conversion,Good Prognosis,E38
Scheduling Problems,Type 1,Melanocytic,40.5,"3,4 - Fibrous Septa",Sarcoma Genetic Profiling,80.5,Fontana-Masson_stain_melanoma,Unknown,1-10 mm,Not Reported,False,8q24.3,65.7,400,ROCK Inhibitor Y-27632,Methylation EPIC to hg38 Liftover,Unknown,E41
Scheduling Problems,Type 1,Neuroectodermal,45.0,"1,2 - Portal Fibrosis",Thyroid Cancer Pathway Analysis,87.2,Orcein_stain_hepatocellular_carcinoma,H3,1-10 mm,alive,True,12p13.2,70.9,435,Hydrocortisone,Methyl-Seq Cross-Platform Normalization,Poor Prognosis,E44
